ArticleIndustrial psychiatry journal
A comparative study evaluating the efficacy of naltrexone versus acamprosate as anticraving agents in alcohol use disorder.
Article in Industrial psychiatry journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Focus on 'Psychiatry and Addiction: A Multi-Faceted Issue'.Brain sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alcohol use disorders (AUDs) are characterized by excessive alcohol consumption, negatively impacting health, social life, and economic status. Globally, AUD contributes to significant disease burden, causing millions deaths annually. Despite the availability of treatments, relapse rates remain high. Naltrexone and acamprosate, two FDA-approved anticraving agents, are widely used to prevent relapse. However, comparative studies in Indian populations are limited, prompting this study to assess the efficacy of these drugs in treating AUD. Aim: This study aimed to compare the effectiveness of naltrexone and acamprosate as anticraving agents in treating AUD, evaluating the time to first drink (lapse) and time to relapse among patients using either medication at 1 and 3 months. It also assessed the correlation between baseline severity of AUD and the efficacy of naltrexone and acamprosate as anticraving agents, as well as compared demographic and clinical variables between the two treatment groups. Materials and Methods: A prospective observational study was conducted on 70 patients diagnosed with AUD, divided into two groups: naltrexone (n = 35) and acamprosate (n = 35). Patients were assessed using the Obsessive Compulsive Drinking Scale (OCDS) and followed for 3 months to evaluate craving intensity, time to first drink, and relapse rates. The Quality of Life Scale (QOLS) and Clinical Global Impression (CGI) were used to assess treatment impact. Results: Both groups were comparable at baseline. At 3 months, naltrexone patients had higher abstinence rates (63.64%) compared with acamprosate (34.68%, Conclusion: Naltrexone demonstrated superior efficacy in maintaining abstinence and reducing relapse rates in AUD patients compared to acamprosate. These findings suggest that naltrexone may be more effective for long-term treatment in the Indian context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.